PATH EX retweeted
Sinead Miller Ph.D. walked away from competitive cycling after a serious brain injury. Motivated by her own trauma, she decided to pursue a career in neuroengineering as CEO of @PATHEXinc . We are proud to be a part of her #founder journey. Learn more: tmc.edu/innovation/accelerat…
Live in 1hr! DeBakey CV Live: #Innovation on the Loose with @DrStuCorr, Dr. Sinead Miller, and Alex Wieseler, as they discuss extracorporeal #bloodfiltration for #sepsis. Watch LIVE: bit.ly/3tWlGD0
@PATHEXinc #medtech
Thank you @AdvaMedUpdate! We are honored to have received this award.
PATH EX retweeted
Alumni Achievements 🏆 @PATHEXinc (MC20 Houston Diamond) won the MedTech Innovator 2021 Execution Award & the AdvaMed Accel Virginia Shimer Rybski Memorial Award.
ow.ly/23oh50GkeeI
PATH EX retweeted
Congratulations to @PATHEXinc and Sinead Miller! 🎉
The #Vanderbilt startup was recently awarded the MedTech Innovator Execution Award!!! #research #sepsis
PATH EX retweeted
Great presentations on infectious disease innovation by @PATHEXinc & @Genetoo_Startup at Pitch Club this evening. The presentations will be available on our YouTube channel tomorrow by 12 MT. #startups #biotech #diagnostics
Thank you, @JLABS. We appreciate your continued support
Very proud of Sinead Miller @PATHEXinc #JLABSTMC company, for being honored on this year’s @cartainc #FastAndCurious2021 list. Read Sinead’s interview, where she discusses her experience and tips for accelerator success: crt.cx/3m91SpO
PATH EX retweeted
When @PATHEXinc was accepted to @JLABS, CEO Sinead Miller knew that moving her whole company to Texas would be a risk. Today, the risk has paid off, as PATH EX aims to change the way we fight deadly infections. Read Sinead's #FastAndCurious2021 interview: crt.cx/3m91SpO
PATH EX retweeted
Meet the honorees:
👏 @guilhemherail -- @hermesrbt
👏 @kushalbyatnal & @josephpalbanese -- @stir
👏 @sindhutweet -- @cognicor
👏 @erinangerer & @NateWyne -- Floodlight Invest
👏 Sinead Miller -- @PATHEXinc
👏 @PratySharma & @prasadkawthekar -- @DashworksAI
PATH EX retweeted
Looking to invest in the ground-breaking world of medical devices? Join @texashalofund on 3/9, as they sit down for a virtual panel with @Adient Medical, @Allotrope_Med, and @PATHEXinc (@MassChallengeTX’s 2020 Diamond Award winner).
#HouTech #MedTech
ow.ly/b09N50DQCgS
Thank you @gordondaugherty! We appreciate your support.
Big congrats to @PATHEXinc for winning the @CapitalFactory prize package award at today's finals of the Venture Houston pitch competition! @HX_VentureFund @HouEX
We are honored to have been selected as a finalist amongst so many amazing companies. Thank you @HouEX!
And the Venture Houston finalists are:
Koda Health
@SparkBiomedical
@PATHEXinc
@conversifi
@CellChorus
@MacroFab
@MainlineEsports
Join us tmr! accelevents.com/e/VentureHou…
#VentureHouston2021 #pitchcompetition #HouTech #houston @HX_VentureFund @ricealliance @Houston_Angels
PATH EX retweeted
#VentureHouston2021 Semi-finals Astros track! Belmont Technologies, @CemvitaFactory @DataGumbo @MacroFab @MainlineEsports @OrbitalTraction @PATHEXinc @SyzygyPlasmonic @topl_protocol @VenusAerospace
PATH EX retweeted
Thank you @MITREcorp!
ICYMI: #BridgingInnovation newsletter highlights 2020 @MassChallenge $100K Diamond Award winner @PATHEXinc of #Houston. @MassChallengeTX
bit.ly/3nK4Tgh
We still can't believe we won the @MassChallenge $100k Diamond award! We cannot recommend this great program enough. #MC20
A big thanks to our partners and supporters @JLABS @TMCInnovation @InnovaMemphis @NSFSBIR @texashalofund
Thank you @MITREcorp!
“Those who value speed, adaptability, and risk-taking will have a deep appreciation for the work of entrepreneurs who live these values every day,” - VP Kerry Buckley, presenting $100K Diamond Award to @PATHEXinc at @MassChallenge Awards. #MC20
PATH EX WINS THE DIAMOND AWARD! Thank you @MassChallengeTX @MassChallenge. You guys are the best! #MC20
We can't thank our mentors and program directors enough!
Thank you @MassChallengeTX for a great program!
This Post is from an account that no longer exists. Learn more



















